1 Introduction
==============

It is now widely accepted that many complex diseases are associated with multiple targets, which in turn affect multiple pathways, requiring the adoption of quantitative systems pharmacology (QSP) approaches for assessing the mechanisms of disease etiology, progression and treatment ([@btaa210-B13]). The possibility of exploiting the promiscuity of drugs via drug repurposing and polypharmacological treatments also emerged in recent years as a means of reducing risk and cost in drug development ([@btaa210-B2]; [@btaa210-B9]; [@btaa210-B12]). In parallel, chemogenomics studies assist in improving our understanding of disease mechanisms and developing therapeutic strategies by providing phenotypic information on ensembles of active compounds screened against families of targets. Such studies underscore the importance of developing computational tools that would harness the rapidly accumulating data to predict new chemical--target interactions (CTIs) over a broad space of chemicals and enable their mapping to pathways and function.

Several resources have been developed in the last decade to address different aspects of the emerging needs but an integrated server designed to automate the association of multiple CTIs with enriched pathways and functions remains to be developed. For example, the servers SEA ([@btaa210-B7]), SwissTargetPrediction ([@btaa210-B4]) and SuperPred ([@btaa210-B8]) predict new CTIs, but not corresponding pathways. DINIES ([@btaa210-B16]) and DT-Web ([@btaa210-B1]) incorporate pathway information, but not large-scale CTIs, their respective data being limited to Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@btaa210-B6]) and DrugBank ([@btaa210-B15]). Furthermore, existing interfaces are not designed to use as input multiple drugs/targets for polypharmacological strategies and/or for complementing chemogenomics efforts.

We developed the QuartataWeb server to address those needs. QuartataWeb uses known (experimentally verified) CTIs from DrugBank and STITCH ([@btaa210-B14]; [Supplementary Table S1](#sup1){ref-type="supplementary-material"} and [Fig. S1](#sup1){ref-type="supplementary-material"}) in a probabilistic matrix factorization algorithm ([@btaa210-B3]) to predict new CTIs in the extended space of more than 300 000 chemicals and 9000 human proteins. The engine parameters have been optimized (see [Supplementary Table S2](#sup1){ref-type="supplementary-material"}) to ensure high CTI prediction accuracy (see [Supplementary Table S3](#sup1){ref-type="supplementary-material"} and [Fig. S2](#sup1){ref-type="supplementary-material"}). The outputs are linked to KEGG pathways and Gene Ontology (GO) annotations (GOAs) ([@btaa210-B5]) to predict the most probable pathways, functions and processes affected by one or more chemicals and to efficiently assist in interpreting and/or guiding chemogenomics and polypharmacological studies.

2 QuartataWeb implementation and pipeline
=========================================

The QuartataWeb server pipeline is schematically depicted in [Figure 1A](#btaa210-F1){ref-type="fig"} and [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}. The server can be flexibly queried with three types of input: (I) a list of chemicals (or targets) for chemogenomics-like screening *in silico* ([Fig. 1A](#btaa210-F1){ref-type="fig"}); (II) one or more pairs of chemicals to be administered in combination for polypharmacological purposes ([Supplementary Fig. S4](#sup1){ref-type="supplementary-material"}); and (III) a single chemical and/or a single target to be characterized ([Supplementary Fig. S4](#sup1){ref-type="supplementary-material"}). In response to a list of chemicals entered in Type I query, QuartataWeb releases newly predicted CTIs and chemical--chemical similarities based on pre-computed latent factor models learned from DrugBank or STITCH data, in addition to retrieving known CTIs from these datasets, as schematically described in [Figure 1A](#btaa210-F1){ref-type="fig"}. The outputted targets are then subjected to target enrichment, which also lead to enrichment scores for associated pathways and GOAs (*P*-values; see Supplementary Theory and Methods\]. The same sequence of tasks can be carried out for a list of targets entered as input. In the case of Type II input, the same tasks are carried out for pairs of chemicals to obtain shared targets, and their enrichment, along with enriched pathways and GOAs ([Supplementary Fig. S4](#sup1){ref-type="supplementary-material"}). Type III input is the simplest query where users enter one chemical, one target or a chemical--target pair to identify associated CTIs, similar chemicals or targets, and enriched pathways and GOAs. Furthermore, the secondary interactions (2°, beyond the immediate neighbors) in the bipartite network of chemical/targets can be visualized. In all cases, outputs are presented as tables with several specifications (e.g. drug/chemical identifiers, Gene IDs and names, PDB IDs, confidence scores and enrichment *P*-values), in addition to visuals such as network representations, bar plots or heatmaps. The force-directed layout in JavaScript D3 package has been customized and designed to interactively display the CTIs and pathways networks.

![QuartataWeb workflow for Type I input, example outputs on CTIs, pathways and GOAs. (**A**) In Type I input, users enter either a list of chemicals or a list of targets of interest. Here, the workflow for a list of chemicals is illustrated. See details in the text. (**B**) Identification of targets (*dark violet dots*, in *yellow ellipse*) shared by four drugs (Input Type I) indicated by *red nodes.* (**C**) KEGG pathways (*green boxes*) corresponding to targets in (B). (**D**) Top 10 enriched GO molecular functions for targets in (B). Bar plot shows enrichment *P*-values. (**E**) Illustration of ligand--target interactions obtained by Type III input. Second generation of nodes with degrees \< 3 are hidden by applying '*Trim 2nd generation nodes'* button. (**F**) Chemical--chemical similarities. The option '*Display secondary interactions*' displays targets shared by selected drugs (*yellow*)](btaa210f1){#btaa210-F1}

3 Applications
==============

**Chemogenomics analysis for a list of chemicals**. In many cases, a set of chemicals exhibiting comparable phenotypes are analyzed in phenotypic screening. Suppose, we are interested in finding out the common mechanism of action of this set of chemicals (Type I input). [Figure 1B](#btaa210-F1){ref-type="fig"} illustrates such a case where four drugs are inputted having same phenotype. QuartataWeb permits to identify the common targets along with the interaction confidence scores and enrichment scores of the targets. One may further learn about the pathways associated with the shared targets ([Fig. 1C](#btaa210-F1){ref-type="fig"}) and corresponding GOAs ([Fig. 1D](#btaa210-F1){ref-type="fig"}). The interface also provides tables with detailed information on the pathways and GOAs, including their *P*-values ([Supplementary Fig. S5](#sup1){ref-type="supplementary-material"}), which could help assessing the dominant pathways and processes that underlie the shared phenotype. Our recent QSP analysis of 50 drugs of abuse serves as an example of the utility of this type of integrated studies ([@btaa210-B11]).

**Polypharmacological evaluation of drug pairs**. Similarly, [Supplementary Figure S6](#sup1){ref-type="supplementary-material"} illustrates the output from QuartataWeb for identifying common targets given pairs of chemicals (Type II input) that trigger comparable responses, e.g. aripiprazole/olanzapine, clozapine/trimipramine, methotrimeprazine/epinastine and cabergoline/mianserin. The corresponding CTIs are listed in tables, and also displayed in a network viewer with an interactive control panel. Links to pathways and GOAs result pages are indicated. In this example, 15 among 192 known and 80 predicted (confidence scores \> 0.9) targets were identified as common targets. Pathways shared by each chemical pair are also listed in the pathway enrichment table. This type of analysis applied to drug combinations used in a Huntington's disease model helped elucidate the origin (shared pathways) of observed synergistic effects ([@btaa210-B10]).

**Drug repurposing or identification of side-effects (Type III)**. Consider loxapine and its target, α2A adrenergic receptor (gene name: ADRA2A) as an example. CTIs corresponding to both drug (*red sphere*) and target (*blue sphere*) can be viewed in peacock representation ([Fig. 1E](#btaa210-F1){ref-type="fig"}), where known and predicted CTIs being distinguished by the *gray* and *red* edges, respectively. Users can interactively select nodes to view primary and 2° interactions. Loxapine is an antipsychotic agent approved for treating schizophrenia, whose primary targets are dopamine and serotonin receptors. The figure displays the 2° interactions of a serotonin receptor (HTR3C, node colored cyan) which turns out to be a target of many drugs associated ADRA2A, some of which are repurposable. Finally, Type III input also permits to identify similar drugs and shared targets as illustrated for the pair doxepin and loxapine ([Fig. 1F](#btaa210-F1){ref-type="fig"}).

4 Conclusion
============

We presented QuartataWeb, an integrated server that offers multiple capabilities for QSP analyses using both known associations and machine-learning predictions. We showed that the interface can help identify repurposable drugs, side-effects, enriched pathways, as well as shared functions, cellular processes and environment for different types of queries. QuartataWeb is expected to serve as a first filter toward designing more effective phenotypic screens and polypharmacological strategies.
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